181 related articles for article (PubMed ID: 17361225)
21. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
Hopfner M; Sutter AP; Huether A; Baradari V; Scherubl H
World J Gastroenterol; 2006 Sep; 12(35):5635-43. PubMed ID: 17007015
[TBL] [Abstract][Full Text] [Related]
22. Protein kinase B modulates the sensitivity of human neuroblastoma cells to insulin-like growth factor receptor inhibition.
Guerreiro AS; Boller D; Shalaby T; Grotzer MA; Arcaro A
Int J Cancer; 2006 Dec; 119(11):2527-38. PubMed ID: 16988940
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.
Ekyalongo RC; Mukohara T; Kataoka Y; Funakoshi Y; Tomioka H; Kiyota N; Fujiwara Y; Minami H
Invest New Drugs; 2013 Apr; 31(2):293-303. PubMed ID: 22828916
[TBL] [Abstract][Full Text] [Related]
24. Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
Premkumar DR; Jane EP; Pollack IF
Int J Oncol; 2010 Sep; 37(3):633-43. PubMed ID: 20664932
[TBL] [Abstract][Full Text] [Related]
25. Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
Manara MC; Landuzzi L; Nanni P; Nicoletti G; Zambelli D; Lollini PL; Nanni C; Hofmann F; García-Echeverría C; Picci P; Scotlandi K
Clin Cancer Res; 2007 Feb; 13(4):1322-30. PubMed ID: 17317844
[TBL] [Abstract][Full Text] [Related]
26. Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
Adachi Y; Li R; Yamamoto H; Min Y; Piao W; Wang Y; Imsumran A; Li H; Arimura Y; Lee CT; Imai K; Carbone DP; Shinomura Y
Carcinogenesis; 2009 Aug; 30(8):1305-13. PubMed ID: 19493905
[TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
[TBL] [Abstract][Full Text] [Related]
28. PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.
Hägerstrand D; Lindh MB; Peña C; Garcia-Echeverria C; Nistér M; Hofmann F; Ostman A
Neuro Oncol; 2010 Sep; 12(9):967-75. PubMed ID: 20378689
[TBL] [Abstract][Full Text] [Related]
29. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Wolf S; Lorenz J; Mössner J; Wiedmann M
World J Gastroenterol; 2010 Jan; 16(2):156-66. PubMed ID: 20066734
[TBL] [Abstract][Full Text] [Related]
30. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.
Whitson BA; Jacobson BA; Frizelle S; Patel MR; Yee D; Maddaus MA; Kratzke RA
Ann Thorac Surg; 2006 Sep; 82(3):996-1001; discussion 1001-2. PubMed ID: 16928523
[TBL] [Abstract][Full Text] [Related]
31. Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
Wu W; Ma J; Shao N; Shi Y; Liu R; Li W; Lin Y; Wang S
PLoS One; 2017; 12(1):e0169229. PubMed ID: 28046018
[TBL] [Abstract][Full Text] [Related]
32. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
[TBL] [Abstract][Full Text] [Related]
33. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
Walsby EJ; Lazenby M; Pepper CJ; Knapper S; Burnett AK
Br J Haematol; 2013 Apr; 161(1):57-67. PubMed ID: 23356405
[TBL] [Abstract][Full Text] [Related]
34. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
Esparís-Ogando A; Ocaña A; Rodríguez-Barrueco R; Ferreira L; Borges J; Pandiella A
Ann Oncol; 2008 Nov; 19(11):1860-9. PubMed ID: 18641009
[TBL] [Abstract][Full Text] [Related]
35. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
[TBL] [Abstract][Full Text] [Related]
36. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Modjtahedi H
BMC Cancer; 2013 Jan; 13():41. PubMed ID: 23367880
[TBL] [Abstract][Full Text] [Related]
37. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
Cell Oncol (Dordr); 2011 Jun; 34(3):245-59. PubMed ID: 21538027
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation.
Huang CT; Chang MC; Chen YL; Chen TC; Chen CA; Cheng WF
Cancer Lett; 2015 Apr; 359(1):117-26. PubMed ID: 25592043
[TBL] [Abstract][Full Text] [Related]
40. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
